Literature DB >> 21585012

[Deficiency of adenosine desaminase (ADA): clinical, biochemical, molecular and treatment aspects].

Jesús Alonso Tintos-Hernández1, Ingrid Patricia Dávalos-Rodríguez.   

Abstract

Adenosine Desaminase (ADA) deficiency, is a purine metabolic disorder that cause severe combined immunodeficiency (SCID) due to the accumulation of toxic metabolites that primarily affects development, differentiation and function of T and B lymphocytes. In addition, some patients show neurological, renal and liver abnormalities, delayed in development, deafness and seizures. If the immune response is not restored, children with this disorder rarely survive; therefore, ADA deficiency must be suspected when difficulty gaining weight, recurrent infections and skeletal abnormalities are present. The ADA deficiency has clinical and immunological characteristics not seen in other immunodeficiencies, data that helps to guide the diagnosis and therapy. This review summarizes clinical, pathological, molecular and treatment findings described in this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585012

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  1 in total

1.  Adenosine Deaminase Deficiency with a Novel Gene Mutation.

Authors:  Maya Gupta; Jahnavi Aluri; Antony Terrance; Manisha Madkaikar
Journal:  Indian J Pediatr       Date:  2016-04-18       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.